Placenta Derived Adherent Cell (PDAC) Interaction and Response on Extracellular Matrix Isolated from Human Placenta
- 0 Comments
- 7379 reads
Cell binding studies. After seeding for 3 hours, similar levels of PDAC attachment were observed on all pECMs (numbers 1–5); the levels of PDAC binding to pECMs were slightly less than that observed on purified collagen. Immunostaining of PDACs for fibronectin at this time revealed abundant intracellular staining, with no detectable extracellular fibronectin (data not shown). As shown in Figure 2, by hour 48 of culture, PDACs increased in number and adopted similar well-spread morphologies on purified collagen,pECM-2,and pECM-4. In contrast, PDACs did not thrive on pECM-1 or pECM-3.Not only were fewer cells observed, but also their morphologies were rounded and not well spread. Pluripotent progenitor cells on pECM-5 appeared more elongated and polarized than PDACs on other pECMs and collagen. Immunostaining for fibronectin at the 48-hour time point revealed an extensive network of extracellular fibronectin matrix fibrils on pECMs numbers 1–4.These fibronectin matrix fibrils were assembled by PDACs; the control pECM-only samples (ie, samples in which PDACs were not cultured on pECM) did not show evidence of fibronectin fibrils. It is also known from the literature that fibronectin deposition into the matrix is a celldependent process and does not occur spontaneously.9 In contrast to pECMs numbers 1–4, pECM-5 and collagen did not support fibronectin matrix assembly by PDACs and no extracellular fibrillar fibronectin was detected on these surfaces.
Cytokine array studies. The secretion of key cytokines/chemokines from PDACs resulting from the binding and proliferation to the pECM was investigated. Cytokine secretion on pECM was compared to that from PDACs incubated on tissue culture treated cell culture plates using a 25-multiplex cytokine array, which includes several interleukins and cytokines (Table 2). Of the 25 cytokines studied, increased secretion of 3 cytokines when on the pECM sheets (compared to tissue culture treated plates or TCP) was observed. These include IL-6, IL-8,and monocyte chemoattractant protein- 1 (MCP-1). Figure 3 (A-C), shows a time-dependent increase in cytokine secretion (IL-6, IL-8, and MCP-1) by PDACs on the 5 pECM constructs; data are normalized to cell numbers present on pECM sheets. Interestingly, pECM-5 was determined to be an anomaly in that there was no increase in MCP-1 secretion. As previously shown, pECM-5 did not support the expression of fibronectin, quite unlike pECM-1 through pECM-4.Taken together, these data suggest a possible change in cellular behavior or signaling when situated on this particular pECM. It is interesting to note that pECM-5 was the only matrix generated without the use of NaOH and had a biochemical composition that maintained the 2 key cell adhesion proteins—fibronectin and laminin.
1. Cabrera-Crespo J, Goncalves VM, Martins EA, Grellet S, Lopes AP, Raw I. Albumin purification from human placenta. Biotechnol Appl Biochem. 2000;31(Pt 2):101–106.
2. Frolik CA, Dart LL, Meyers CA, Smith DM, Sporn MB. Purification and initial characterization of type beta transforming growth factor from human placenta. Proc Natl Acad Sci U S A. 1983;80(12):3676–3680.
3. Li S, Li F,Tan W,Yang N, Jin H, Chen H.An improved, inexpensive method for the large-scale purification of human nerve growth factor. Biotechnol Appl Biochem. 1998;28(Pt 3):215–218.
4. Rhodes RK, Miller EJ. Evidence for the existence of an alpha 1(V) alpha 2(V) alpha 3(V) collagen molecule in human placental tissue. Collagen Relat Res. 1981;1(4):337-343.
5. Edinger J,Ye Q, Paludan C,Wang JL, Hofgartner W, Hariri R. Characterization of placenta derived adherent cells (PDAC): a novel type of stem cells isolated from human placenta. American Society of Hematology, 48th Annual Meeting; December 9–12, 2006; Orlando, Fla.
6. Gharaee-Kermani M, Phan SH. Links role of cytokines and cytokine therapy in wound healing and fibrotic diseases. Curr Pharm Design. 2001;7(11):1083–1103.
7. Hariri RJ, Kaplunovsky AM, Murphy PA. Collagen biofabric and methods of preparing and using the collagen biofabric. US Patent Application Publication No. 20030187515. 2003.
8. Hariri RJ, Kaplunovsky AM, Murphy PA. Collagen biofabric and methods of preparing and using the collagen biofabric. US Patent Application Publication No. 20040048796. 2004.
9. Velling T, Risteli J,Wennerberg K, Mosher DF, Johansson S. Polymerization of type I and III collagens is dependent on fibronectin and enhanced by integrins alpha 11beta1 and alpha 2beta 1. J Biol Chem. 2002;277(40):37377–37381.
10. Dinh T, Pham H,Veves A. Emerging treatments in diabetic wound care.WOUNDS. 2002;14(1):2–10.
11. Bennett NT, Schultz GS. Growth factors and wound healing: Part II. Role in normal and chronic wound healing. Am J Surg. 1993;166(1):74–81.
12. Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med. 1999;341(10):738–746.
13. Grinnell F. Fibronectin and wound healing. J Cell Biochem. 1984;26(2):107–116.
14. Rollins BJ. Chemokines. Blood. 1997;90(3):909–928.
15. Gerszten RE, Garcia-Zepeda EA, Lim YC, et al. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature. 1999;398(6729):718–723.
16. Fahey TJ 3rd, Tracey KJ, Tekamp-Olson P, et al. Macrophage inflammatory protein 1 modulates macrophage function. J Immunol. 1992;148(9):2764–2769.
17. Low QE, Drugea IA, Duffner LA, et al.Wound healing in MIP-1alpha (-/-) and MCP-1(-/-) mice. Am J Path. 2001;159(2):457–463.
18. Rennekampff HO, Hansbrough JF, Kiessig V, Dore C, Sticherling M, Schroder JM. Bioactive interleukin-8 is expressed in wounds and enhances wound healing. J Surg Res. 2000;93(1):41–54.
19. Lin ZQ,Kondo T, Ishida Y,Takayasu T, Mukaida N. Essential involvement of IL-6 in the skin wound-healing process as evidenced by delayed wound healing in IL-6-deficient mice. J Leukoc Biol. 2003;73(6):713–721.
20. Gallucci RM, Simeonova PP, Matheson JM, et al. Impaired cutaneous wound healing in interleukin-6 deficient and immunosuppressed mice. FASEB J. 2000;14(15):2525–2531.